Navigation Links
Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference

ads were evaluated and representative samples of lung tissues were analyzed for pathologic changes.

Examination of the lungs revealed evidence of a dose-related reduction of infection-related pneumonia. Two of the three animals in the highest dosing group showed no evidence of lung infection to the naked eye, while lower-dose groups did show visible infection. This dose-related response was noteworthy given that viral loads were consistent among the subjects receiving the various dosages and the control group. Ten days of ongoing Alferon-LDO prophylaxis and treatment reduced the severity of pneumonia despite the continuing presence of the influenza virus.

The study results are being presented at the ongoing 2nd International Conference on Avian Influenza, being held at the Pasteur Institute.

Recent medical reports from critical influenza regions such as Southeast Asia indicate that presently available therapies, even given at the highest doses available via intravenous routes, do not alter the avian influenza death rate, which at present is greater than 60%. Given the danger of an avian flu pandemic, the lack of an effective available therapy and the fact that Alferon-N(TM) is already approved by the United States FDA as safe and effective in treating a different virus, Hemispherx management is hopeful that Alferon-LDO can receive expedited review and emergency-based approval as an anti-HPAI agent, solely relying on the "animal rule" for demonstration of efficacy.

"The threat of global pandemic illness from infectious disease puts the highest possible priority on finding therapeutic strategies that can protect first responders and save patient lives," commented Dr. William Carter, Chairman and Chief Executive Officer of Hemispherx. "We are encouraged by the strong potential that Alferon-LDO, an experimental formulation of our previously licensed drug, shows as a prophylactic agent, especially for front-line health care workers, and its ad
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:5/22/2015)... 22, 2015  In a sweeping analysis assessing the ... T1D Exchange researchers conclude that there remains considerable ... across all age groups, but especially for adolescents and ... of diabetes treatment, underscoring the need to address barriers ... can help type 1 patients achieve optimal metabolic control. ...
(Date:5/21/2015)... , May 21, 2015  When ... along the side of his neck, he ... took a couple weeks off from weight ... go away.                               A ... 26, was referred to Michel Kliot, ...
(Date:5/21/2015)... , May 21, 2015  Cardica, Inc. (Nasdaq: CRDC ... Greg Watson , the company,s vice president of operations, ... company,s common stock, at a per share exercise price of ... stock option was granted pursuant to Cardica, Inc.,s Inducement Plan, ... May 2015 under Rule 5653(c)(4) of the Nasdaq Global Market ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4Cardica Announces New Employment Inducement Grant 2
... Dec. 29, 2010 Reportlinker.com announces that a new ... Mammography World Markets ... poised for a major new phase of growth fueled ... the computer and digital areas and the higher interest ...
... (Nasdaq: OMER ), a biopharmaceutical company ... on inflammation and disorders of the central nervous ... clinical trial of OMS201, the Company,s urological PharmacoSurgery™ ... an anti-inflammatory agent and a smooth muscle relaxant, ...
Cached Medicine Technology:Reportlinker Adds Mammography World Markets 2Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy 2Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy 3
(Date:5/24/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, ... sees many patients for concerns about hair loss. ... loss, it is clear that there are environmental factors ... of hormone that can contribute. Since they offer a ... aspects of the peri and post-menopausal woman, they can ...
(Date:5/24/2015)... EnviroLeather™ by LDI, a leader in ... classic, rugged leather grain with enhanced stain resistance ... ink, to be easily removed. The collection is ... healthcare, hospitality and education environments. , InkGard Plus ... developing products that are more sustainable, less toxic ...
(Date:5/24/2015)... 2015 Medicx Media Solutions ... executive Jay Krihak as its head of programmatic ... up its expertise and leadership position in the ... Health sectors. , Krihak is an experienced, award-winning ... Krihak led sales planning teams for mobile platform ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation organized a ... learned through meditation and initiation at Special Holistic School ... Yogamaatha, a nine-year-old girl from North Carolina, stunned an ... the 2015 Business Advocacy Summit at Capitol Hill in ... In a demonstration that lasted three hours, Yogamaatha was ...
(Date:5/23/2015)... May 23, 2015 On May 16, the ... The event was a 5k mud obstacle run that raised ... 2 million people worldwide, and the reason we participated was ... Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred percent of ... Society.” , The event was not only attended by eXtreme ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
... part of health, and assessment of sleep habits should be ... in the September 18 issue of Archives of Internal Medicine ... devoted to studies of sleep and health. ,"The ... as an indicator of health and quality of life and ...
... the times, warns the U.S. Food and Drug Administration// (FDA). ... Georgia that was believed to occur due to the consumption ... three cases were reported on September 15. Other consumers of ... not have any complaints as they had properly refrigerated it., ...
... official government assessment of a ?1 million public consultation project ... fake//. ,Your Health, Your Care, Your Say was ... a say in a White Paper on health published this ... complained that they had no influence on the final policies.14% ...
... A recent report by the Ministry in Jamaica has revealed ... a paper that has now come before the House of// ... virus live healthy lives for several years without developing the ... the performance of the National HIV/STI Control Programme, and states ...
... lot more funds are needed from the rich countries to ... five by two-thirds.// ,Five times more money is ... one of the series of papers published online by the ... the journal, UNICEF and the Norwegian government. , ...
... to improve HIV/AIDS treatment and evolve better prevention strategies, ... into an agreement this month, to formally seal their ... free nation. It is well known that, The Clinton ... to eliminate AIDS from the planet. ...
Cached Medicine News:Health News:Incorporate Sleep Evaluation into Routine Medical Care 2Health News:A million Pound Public consultation - declared a sham!! 2Health News:Child death reduction needs five times more funds 2
... For fast, single-solution staining, Hema-Quik ... Dip slides into stain solution ... transfer to deionized water for ... a second time by dipping ...
This stain is the McNeal formula and can be substituted for Wright Stain solution....
This Wright-Giemsa is a dual-use stain for peripheral blood and bone marrow smears. It produces somewhat darker results when compared with Giemsa, particularly in the blue to magenta shades....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Medicine Products: